Who’s more likely to be PDC focused over ADCs21 Oct 2025 21:51
Short answer: almost none of the true “tier-one” pharmas have zero exposure — ADCs are now a mainstream strategic area and virtually every big pharma has at least some programs, partnerships or M&A to get into the space. That said, degrees of commitment vary, and the firms most likely to be willing/“brave” to back peptide-drug conjugates (PDCs) next are the ones that (a) have shown appetite for platform M&A/partnerships and (b) are experimentally open to non-antibody delivery modalities.
Quick evidence (highlights)
• Roche/Genentech remain a lead ADC player (Polivy, other combinational ADC activity). 
• AstraZeneca (Enhertu, Datroway) has doubled down on ADCs and is aggressively developing the class. 
• AbbVie paid big ($10.1B) to acquire ImmunoGen — a clear “all in” style move. 
• Johnson & Johnson completed a $≈$2B Ambrx buy to accelerate next-gen ADCs — another major commitment. 
• Many other big groups (Pfizer, Sanofi, GSK, etc.) have ADC deals or internal programs — some have had setbacks (Pfizer recently took impairment charges on ADC work) but still maintain ADC strategies. 
So — who hasn’t gone “all in”?
There isn’t a clean answer that names one blue-chip pharma that has no ADC commitment. Even companies that look relatively “light” on ADCs in public perception (for example, some of the older vaccine-oriented groups) still maintain partnerships or exploratory ADC programs. The practical takeaway: every tier-one firm has at least dipped in — some via big acquisitions (AbbVie, J&J), some via in-licensing/partnerships (Sanofi, GSK), and some by keeping internal R&D lines (Pfizer, Roche, AstraZeneca). 
Who’s most likely to adopt/support PDCs next?
PDCs (peptide-drug conjugates) are an emerging, fast-growing niche (market reports and reviews show rising interest). Big pharmas likely to back them are those that:
• already partner aggressively with niche biotech and buy platform companies (J&J, AbbVie patterns); or
• have shown willingness to diversify beyond antibodies into peptides/radioligands/novel modalities (Novartis, Pfizer, Sanofi, AstraZeneca); or
• have active peptide-technology capabilities or peptide pipelines.
Concretely, the early adopters most probable are:
1. Johnson & Johnson — demonstrated by big, targeted platform buys (Ambrx) and active partnering; J&J has the M&A appetite and development scale to fold PDC tech in. 
2. Pfizer — large oncology footprint, manufacturing capacity and recent strategic resets after ADC setbacks — likely to back promising alternative conjugate platforms if the data look compelling. (Pfizer has been explicit about ADCs as an oncology focus while also writing down failed programs.) 
3. Sanofi / Novartis / AstraZeneca — each already works with external ADC platforms and has shown openness to novel targeted modalities; they’d be natural partners for PDC specialists.
Sign In
Follow the stocks
